J Gastroenterol Hepatol:MRE在预测慢性肝病患者腹水存在方面具有较高的诊断效能

2018-04-12 MedSci MedSci原创

与血清纤维化标志物相比,MRE在预测腹水存在方面具有较高的诊断效能。基于肝硬度测量的LSMRE具有预测CLD患者腹水存在的潜力。

研究目的:本研究旨在评估磁共振弹性成像(MRE)是否能作为一种非侵入性方法预测慢性肝病(CLD)患者是否会发生腹水。

研究方法:从2013年3月至2015年6月,208例CLD患者进行了肝硬度测量。采用受试者工作特征(ROC)曲线评价MRE预测患者发生腹水的诊断效能,并与其他血清纤维化标志物的表现进行比较。进行多因素logistic回归分析,以确定与腹水存在相关的危险因素。在基线时,对无腹水的患者出现腹水的累积发病率进行了检查。81例CLD患者行病理组织学诊断,对肝纤维化病理分期进行评价。

研究结果:在208例患者中,41例患者发生腹水。存在腹水的最佳LS临界值为6.0 kPa (ROC曲线下面积= 0.87)。出现腹水时,MRE的ROC曲线下面积显著高于其他肝纤维化标志物的曲线下面积。多因素分析显示,LS >6.0 kPa是腹水存在的独立危险因素。LS值>6.0 kPa的患者,腹水累积发生率显著增高。在诊断肝纤维化分期≥4的患者时,MRE相比于其他肝纤维化指标的准确性更高。

研究结论:与血清纤维化标志物相比,MRE在预测腹水存在方面具有较高的诊断效能。基于肝硬度测量的LSMRE具有预测CLD患者腹水存在的潜力。

原始出处:

Abe K, Takahashi A, Imaizumi H, et al. Utility of magnetic resonance elastography for predicting ascites in patients with chronic liver disease. J Gastroenterol Hepatol, 2018, 33(3), 733-740. doi: 10.1111/jgh.13927.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2072130, encodeId=794620e2130e6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jun 06 14:14:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064362, encodeId=279f2064362d1, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 15 07:14:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017943, encodeId=24c2201e943f4, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Feb 16 18:14:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649498, encodeId=16c5164949843, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Mon Jul 30 01:14:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711448, encodeId=b2d01e1144871, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 29 13:14:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427079, encodeId=a96b142e07996, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Apr 14 13:14:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
    2018-06-06 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2072130, encodeId=794620e2130e6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jun 06 14:14:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064362, encodeId=279f2064362d1, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 15 07:14:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017943, encodeId=24c2201e943f4, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Feb 16 18:14:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649498, encodeId=16c5164949843, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Mon Jul 30 01:14:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711448, encodeId=b2d01e1144871, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 29 13:14:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427079, encodeId=a96b142e07996, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Apr 14 13:14:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2072130, encodeId=794620e2130e6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jun 06 14:14:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064362, encodeId=279f2064362d1, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 15 07:14:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017943, encodeId=24c2201e943f4, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Feb 16 18:14:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649498, encodeId=16c5164949843, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Mon Jul 30 01:14:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711448, encodeId=b2d01e1144871, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 29 13:14:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427079, encodeId=a96b142e07996, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Apr 14 13:14:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2072130, encodeId=794620e2130e6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jun 06 14:14:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064362, encodeId=279f2064362d1, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 15 07:14:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017943, encodeId=24c2201e943f4, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Feb 16 18:14:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649498, encodeId=16c5164949843, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Mon Jul 30 01:14:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711448, encodeId=b2d01e1144871, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 29 13:14:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427079, encodeId=a96b142e07996, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Apr 14 13:14:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
    2018-07-30 freve
  5. [GetPortalCommentsPageByObjectIdResponse(id=2072130, encodeId=794620e2130e6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jun 06 14:14:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064362, encodeId=279f2064362d1, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 15 07:14:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017943, encodeId=24c2201e943f4, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Feb 16 18:14:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649498, encodeId=16c5164949843, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Mon Jul 30 01:14:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711448, encodeId=b2d01e1144871, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 29 13:14:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427079, encodeId=a96b142e07996, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Apr 14 13:14:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2072130, encodeId=794620e2130e6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jun 06 14:14:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064362, encodeId=279f2064362d1, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 15 07:14:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017943, encodeId=24c2201e943f4, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Feb 16 18:14:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649498, encodeId=16c5164949843, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Mon Jul 30 01:14:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711448, encodeId=b2d01e1144871, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 29 13:14:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427079, encodeId=a96b142e07996, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Apr 14 13:14:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
    2018-04-14 gwc384

相关资讯

J Hepatol:生存率不降反升 卡维地洛对失代偿性肝硬化和腹水患者无害

2017年7月,发表在《J Hepatol》的一项由英国科学家进行的研究表明,失代偿性肝硬化和腹水患者使用卡维地洛是安全的,并且提高了轻度腹水患者的生存率。

腹胀1年半,加重1个月,不仅是糖尿病

患者老年男性,慢性起病,表现为大量胸腹腔积液,胸腔积液以右侧为主,肝大,双下肢水肿。

3个病例8副图,让你掌握腹水的疑难病因!

腹水又称腹腔积液,指因某些疾病所引起的腹腔内液体积聚过多,临床工作中经常碰到腹水的患者。引起腹水的原因较多,如肝硬化、结核性腹膜炎、恶性肿瘤、胰源性腹水等。正因腹水病因的多样性,临床诊断难易程度不尽相同。

肝淀粉样变性死亡1例

患者女性,48岁,因“乏力、纳差,伴肝区不适”于2012年4月7日入本院就诊。

肿瘤患者出现腹水咋处理?

癌性腹水会加重晚期患者的恶液质状态,严重影响患者的生活质量,因此临床需对恶性腹水进行综合性对症处理,最大程度改善患者生存质量及生存时间。